Third-party literature and database links do not constitute endorsement of a use or result
Ann Gastroenterol (2015) 28:2039
Other ingredients: vegetable cellulose (capsule), acacia fiber, guar fiber, rosemary extract, microcrystalline cellulose, silica
The SUSTAIN trials assessed final once-weekly doses of 1.0 mg only, or 0.5 mg and 1.0 mg, of subcutaneous semaglutide ( Once-weekly subcutaneous semaglutide was compared with placebo ( Across the SUSTAIN program, the primary and confirmatory secondary endpoints for most trials were change from baseline in HbA 1c and body weight, respectively, to the end of treatment (30, 40, 52, or 56 weeks) ( 1c and body weight, respectively ( 1c Set al
321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body." FDA's letters to the other manufacturers are similar in their complaints about why their products fall under the agency's regulatory oversight and why the companies are not allowed to market them, despite their oft-cited claims that the products, especially the triple agonists, are for research only